X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DZD9008 (sunvozertinib) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic non-small cell lung cancer.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
The partnership aims to accelerate the development of DZD9008 (sunvozertinib), an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity, for patients with EGFR Exon20ins mutant NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dizal Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 06, 2023
Details:
DZD9008 (sunvozertinib) is an investigational, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) exon20 insertion (exon20ins) mutations for the treatment of advanced NSCLC.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
DZD9008 (sunvozertinib) also demonstrated a favorable safety profile, Of all 277 patients in the safety set, the most common treatment-related adverse events were diarrhea and rash, the majority of which were Grade 1/2 and clinically manageable.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
Updated findings from the studies, in platinum-pretreated patients (n=119), the best ORR (at the RP2D of 300mg QD) assessment according to RECIST guidelines (version 1.1) was 52.4%. In patients with baseline brain metastasis, the best ORR at 300 mg QD reached 44%.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2022
Details:
Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures. It also demonstrates superior efficacy in patients after platinum and anti-PD(L)1 treatment failures.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
DZD9008 (sunvozertinib) shows potent antitumor activity against EGFR exon20ins mutations at enzymatic and cellular levels, and in patient-derived xenograft and transgenic animal models.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
DZD9008 (Sunvozertinib), is a rationally designed selective, irreversible, novel EGFR inhibitor. It also shows efficacy among patients with brain metastasis or previously treated by Amivantamab.
Lead Product(s): Sunvozertinib
Therapeutic Area: Oncology Product Name: DZD9008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
